AI-Designed Obesity and Diabetes Drug Candidate Clears Preclinical Hurdle

Insilico Medicine has announced the nomination of ISM1354, an AI-generated small molecule targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), as a preclinical candidate for obesity, type 2 diabetes, and broader cardiometabolic disease. This development is significant because cardiometabolic conditions are among the leading drivers of age-related functional decline and mortality, and new therapeutic approaches in this space could meaningfully extend healthspan.

The preclinical data package is notably strong on pharmacokinetic grounds. ISM1354 achieved oral bioavailability of 75–104% across mice, rats, dogs, and monkeys — a range rarely seen across multiple species simultaneously — and at the same dose delivered at least 18 times greater plasma exposure than a clinical-stage benchmark compound. High and consistent oral bioavailability is a major practical advantage for any chronic disease drug.

Safety signals also appear favorable. The compound showed substantially weaker inhibition of the hepatic transporter OATP1B1 compared to the benchmark, which matters because OATP1B1 inhibition can cause drug-drug interactions and liver toxicity. Minimal hepatocyte cytotoxicity was observed at concentrations up to 200 μM, versus benchmark IC50 values of roughly 25 μM in human hepatocytes — a meaningful margin. A non-GLP monkey toxicology study estimated a 45-fold safety margin.

The compound was designed using Insilico's Chemistry42 AI platform, which integrates multi-objective molecular generation, free energy perturbation calculations, drug-induced liver injury screening, and iterative design-make-test-analyze cycles. This AI-first pipeline is central to the company's claim of accelerating drug discovery timelines and reducing attrition.

ISM1354 is now advancing to formal GLP toxicology studies, a prerequisite for first-in-human trials. Investors and researchers should note this remains early-stage: all data are preclinical, and human efficacy and safety are unproven. Nonetheless, the pharmacokinetic and safety profile positions ISM1354 as a credible candidate in the competitive metabolic disease space.